We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Merck & Co.'s antiviral business suffered some serious blows this year, but it now boasts a brand-new drug: Prevymis, a cytomegalovirus fighter now FDA-approved to prevent infection in adults undergoing stem cell transplants.